Scandinavian ChemoTech receives final patent approval in the EU for the tumour specific control unit in our TSE™ platform
The Company has received the final approval for its EU patent which includes the tumour specific control unit and safety features that are crucial for our TSE platform. The innovation is designed to reduce the side effects which normally occur with older electroporation and ablative technologies.This patent further strengthens ChemoTech’s TSE technology and protects the crucial control unit that generates the unique TSE pulse. The control unit helps the treating physicians of both IQwave™ and vetIQure™ to reduce necros[1] and improve apoptosis[2]. The concept of TSE is to establish